BioCentury | Dec 23, 2020
Product Development
Dec. 21-23 Quick Takes: readouts for Genentech, Rhythm, ChemoCentryx and BMS
...of the MC4R, a melanocortin receptor. ChemoCentryx plots path forward following Phase II miss in C3 glomerulopathy ChemoCentryx Inc....
...progression-free survival in September 2019.TARGETSANG2 (ANGPT2) – Angiopoietin 2C5AR1 (C5AR; CD88) – Complement receptor 5A BC Staff ChemoCentryx Inc....
...progression-free survival in September 2019.TARGETSANG2 (ANGPT2) – Angiopoietin 2C5AR1 (C5AR; CD88) – Complement receptor 5A BC Staff ChemoCentryx Inc....